Roughly 7.1 million of the 18.7 million new cancer cases recorded worldwide in 2022 were tied to risk factors that people, governments, and health systems can act on. That figure, 37.8 percent of all new diagnoses, comes from a study spanning 30 modifiable risk factors, 36 cancer types, and 185 countries. The gap between men and women is striking: 45.4 percent of cancers in men traced to preventable causes, compared with 29.7 percent in women.
Why the 37.8 percent finding demands a policy response right now
The raw number behind the headline is large enough to reshape how countries spend their cancer budgets. If nearly four in ten cases link to factors such as tobacco use, infections, alcohol, diet, and air pollution, then prevention programs are not a secondary priority. They are the front line. The World Health Organization and the International Agency for Research on Cancer framed the data in exactly those terms in a joint news release stating that four in ten cancer cases could be prevented globally.
The 15.7 percentage-point gap between men and women carries its own policy signal. Tobacco alone accounts for 15 percent of all preventable cancer cases, and infections account for another 10 percent. Because tobacco use and certain infection exposures skew heavily toward men in many regions, countries that paired tobacco tax increases with expanded HPV vaccination between 2015 and 2022 would logically narrow that male-female gap faster than countries that relied on screening alone. Screening catches disease after it starts. Taxes and vaccines attack the causes before tumors form. The data published in the Nature Medicine study do not break out country-level attributable fractions in publicly available tables, so testing that hypothesis precisely remains difficult. But the direction of the evidence is clear: structural interventions that cut exposure rates should shrink the preventable share for both sexes, with the steeper drop among men.
Thirty risk factors across 185 countries in one dataset
The core analysis, published in Nature Medicine, used population-attributable fraction methods to estimate how many 2022 cancer cases would not have occurred if specific exposures had been eliminated. The researchers drew on WHO databases for exposure inputs, including ambient air-pollution measurements compiled through the organization’s monitoring program and alcohol-consumption tables that convert per-capita litre figures into grams-per-day estimates for drinkers aged 15 and older.
The study’s scope, 30 modifiable risk factors and 36 cancer types, is wide enough to capture the main drivers of preventable cancer in every WHO region. Tobacco led the list at 15 percent of attributable cases. Infections, including hepatitis B, hepatitis C, and human papillomavirus, followed at 10 percent. Alcohol contributed roughly 3 percent. Air pollution, diet, and physical inactivity filled out much of the remaining share. Regional variation was substantial: cancer registries compiled in IARC’s Cancer Incidence in Five Continents volumes show that the mix of dominant risk factors shifts from sub-Saharan Africa, where infections drive a larger proportion, to high-income countries, where tobacco and metabolic risks dominate.
Reporting in The BMJ stressed that calling cancers “preventable” does not mean patients are to blame for their diagnoses. Study authors quoted in that coverage emphasized the need for structural and policy solutions, not individual guilt. That distinction matters because framing prevention as personal responsibility can discourage public investment in the population-level tools, such as taxation, vaccination programs, and pollution controls, that actually move exposure rates.
What the 2022 cancer data still cannot tell us
Several questions remain open. The Nature Medicine paper provides global and sex-disaggregated estimates, but granular country-level attributable-fraction tables have not been made publicly available in the summaries released so far. Without those tables, researchers and policymakers in individual nations cannot easily compare their preventable burden against peer countries or track progress from one assessment cycle to the next.
The exposure datasets themselves carry inherent uncertainty. Air-pollution estimates rely on ground-monitoring stations supplemented by satellite-derived readings, and coverage gaps persist in low-income settings. Alcohol-consumption data depend on survey self-reports and trade statistics, both of which can undercount actual intake. The study authors acknowledged these limitations, but the practical effect is that the 37.8 percent figure is best understood as a carefully constructed estimate rather than a precise census of preventable cases.
The WHO’s own cancer overview rounds the same finding to approximately 38 percent, reinforcing the alignment between the new study and the organization’s standing assessment. That consistency strengthens confidence in the headline number even as the underlying input data carry margins of error.
What this means for individuals and health systems
For anyone weighing personal health decisions, the message is not that cancer can always be avoided by “doing everything right.” Many cancers arise without any known modifiable cause, and even people who never smoke or drink can develop the disease. The new estimates instead highlight where risk can be reduced in ways that are both realistic and evidence-based.
On an individual level, the largest levers look familiar: avoiding tobacco in all forms, limiting alcohol intake, staying up to date on recommended vaccines such as HPV and hepatitis B, and seeking testing and treatment for chronic infections when available. Reducing exposure to second-hand smoke and heavy air pollution can be harder for individuals to control, which is why public policies on clean air and smoke-free environments remain so important.
For health systems, the findings argue for rebalancing cancer strategies that have historically leaned toward late-stage treatment. Expanding access to affordable tobacco-cessation support, integrating vaccination into routine primary care, and enforcing environmental regulations are all comparatively low-cost measures when weighed against the expense of chemotherapy, radiotherapy, and complex surgery. The study’s global framing also suggests that prevention investments in low- and middle-income countries could yield especially large gains, because infection-related cancers and high smoking prevalence often coexist with limited treatment capacity.
Designing those policies will require more granular data than the current global estimates provide. National cancer registries, better surveillance of risk-factor trends, and transparent sharing of attributable-fraction methods could help countries track whether prevention efforts are actually shrinking their share of modifiable cancers over time. Until then, the 37.8 percent figure should be treated as both a warning and an opportunity: a reminder of the scale of preventable suffering, and a prompt for governments to move prevention from the margins of cancer policy to its center.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
